Who is sponsoring NCT02576925?

NCT02576925 is sponsored by Fondation Ophtalmologique Adolphe de Rothschild.

What drugs are being tested in NCT02576925?

Interventions in NCT02576925: Clinical, ophthalmological and neurological evaluation.

Is NCT02576925 still recruiting?

NCT02576925 is currently recruiting now. Last updated 25 June 2025.

Last reviewed 2025-06-25 · How we verify

NCT02576925: VASCO-DIP

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Predictive Score for the Ischemic Etiology of a Transient Diplopia (VASCO-DIP)

Recruiting now Last updated 25 June 2025

What this trial tests

trial testing Clinical, ophthalmological and neurological evaluation in Diplopia in 220 participants. Currently enrolling.

Timeline

24 September 2015

Primary endpoint
23 September 2025

23 December 2025

Quick facts

Lead sponsor	Fondation Ophtalmologique Adolphe de Rothschild
Status	Recruiting now
Study type	OBSERVATIONAL
Enrollment	220
Start date	24 September 2015
Primary completion	23 September 2025
Estimated completion	23 December 2025
Sites	2 locations across France

Drugs / interventions tested

Clinical, ophthalmological and neurological evaluation

Conditions studied

Diplopia — all drugs for Diplopia →

Sponsor

Fondation Ophtalmologique Adolphe de Rothschild — full company profile →

Who can join

18 and older, any sex, with Diplopia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The transient diplopias (TD) is defined by a short diplopia. Their etiology may be ophthalmological, neurological non-ischemic or of ischemic origin. The difficulty is to recognize an ischemic mechanism which imposes emergency cares. A clinical score could help the clinician to recognize the etiology of the TD .

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Fondation Ophtalmologique Adolphe de Rothschild trials

Trials by the same sponsor.

NCT04701619 — Immuno-inflammatory Profile and Response to Ischemic Stroke Reperfusion Therapies (IMMUNOSTROKE) · NA · not yet recruiting
NCT04763161 — Immuno-inflammation in the Acute Phase of an Ischaemic Cerebral Accident Managed by Decompressive Hemicraniectomy: a Cas · not yet recruiting
NCT06264531 — Efficacy and Safety of Anti-angiogenic Therapy With IV Bevacizumab in Patients With Symptomatic Cerebral Arteriovenous M · Phase 2, PHASE3 · recruiting
NCT06895044 — Evolution of Ocular Growth in Myopic Children: A Prospective Cohort Study · recruiting
NCT06644196 — Creation of a Database of Images of the Eye With the Holographic Doppler Laser · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02576925 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Fondation Ophtalmologique Adolphe de Rothschild
Last refreshed: 25 June 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02576925.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing